Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure

Thrombosis Journal

Volumn 18, Issue 1, 2020, Pages

  Kawano, Noriaki ^a   Wada, Hideo ^b   Uchiyama, Toshimasa ^c   Kawasugi, Kazuo ^d   Madoiwa, Seiji ^e   Takezako, Naoki ^f   Suzuki, Kei ^g   Seki, Yoshinobu ^h   Ikezoe, Takayuki ⁱ   Hattori, Tsuyoshi ^j   Okamoto, Kohji ^k  

^a MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^b Mie Pref General Medical Center   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION TAKASAKI GENERAL MEDICAL CENTER   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e SAISEIKAI CENTRAL HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

^g MIE UNIVERSITY HOSPITAL   (Japan)

^h NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

ⁱ FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^j ASAHI KASEI PHARMA CORPORATION   (Japan)

^k KITAKYUSHU CITY YAHATA HOSPITAL   (Japan)

more..

Author keywords

Bilirubin; Creatinine; DIC; Hematological malignancy; Infectious disease; SOFA

Indexed keywords

ANTITHROMBIN; BILIRUBIN; CREATININE; LACTATE DEHYDROGENASE; RECOMBINANT THROMBOMODULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NEWBORN; OVERALL SURVIVAL; POSTMARKETING SURVEILLANCE; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT OUTCOME;

EID: 85079289406     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-020-0216-6     Document Type: Article

References (34)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586-92.
2. Bick RL. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis and treatment. Hematol Oncol Clin North Am. 2003;17:149-76.
3. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037. https://doi.org/10.1038/nrdp.2016.37.
4. Ikezoe T. Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. J Intensive Care. 2015;3:1. https://doi.org/10.1186/s40560-014-0050-7.
5. Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol. 2014;100:27-37. https://doi.org/10.1007/s12185-013-1463-0.
6. Wada H, Thachil J, Di Nisio M, Kurosawa S, Gando S, Toh CH. The scientific standardization committee on DIC of the international society on thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:2078-9. https://doi.org/10.1111/jth.12366.
7. Wada H, Asakura H, Okamoto K, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee.Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6-11.
8. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24-33.
9. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41.
10. Mimuro J, Takahashi H, Kitajima I, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013;131:436-43.
11. Asakura H, Takahashi H, Tsuji H, et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res. 2014;133:364-70.
12. Eguchi Y, Gando S, Ishikura H, et al. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care. 2014;2:30.
13. Wada H, Okamoto K, Iba T, et al. Addition of recommendations for the use of recombinant human thrombomodulin to the "expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res. 2014;134:924-5. https://doi.org/10.1016/j.thromres.2014.07.033.
14. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45:486-552. https://doi.org/10.1097/CCM.0000000000002255.
15. Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a recombinant human soluble Thrombomodulin on mortality in patients with Sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321:1993-2002. https://doi.org/10.1001/jama.2019.5358.
16. Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508-19. https://doi.org/10.1111/jth.12841.
17. Yamakawa K, Levy JH, Iba T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Crit Care. 2019;23:302. https://doi.org/10.1186/s13054-019-2587-2.
18. Okuda A, Ogura T, Imanishi M, et al. Clinical impact of recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholangitis. Gut Liver. 2018;12:471-7. https://doi.org/10.5009/gnl17489.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
20. Dempfle CE, Wurst M, Smolinski M, et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost. 2004;91:812-8.
21. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94:975-9.
22. Kotajima N, Kanda T, Fukumura Y, et al. Serum thrombomodulin as a prognostic marker of disseminated intravascular coagulation. J Med. 1999;30:19-29.
23. Gando S, Saitoh D, Ogura H, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAMDIC) study group: natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008;36:145-50.
24. Seki Y, Wada H, Kawasugi K, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee: a prospective analysis of disseminated intravascular coagulation in patients with infections. Intern Med. 2013;52:1893-8.
25. Kawano N, Tasaki A, Kawano S, et al. Sequential organ failure assessment (SOFA) score as a prognostic factor for disseminated intravascular coagulation patients with infectious disease treated with recombinant human soluble thrombomodulin (rhTM) in clinical practice. Japanese J Transfus Cell Ther. 2017;63:763-79.
26. Ohshiro M, Kuroda J, Kobayashi Y, et al. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin. Am J Hematol. 2012;87:116-9.
27. Yamakawa K, Umemura Y, Hayakawa M, et al. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20:229.
28. Nakashima T, Miyamoto K, Shimokawa T, et al. The association between sequential organ failure assessment scores and mortality in patients with sepsis during the first week: the JSEPTIC DIC study. J Intensive Care. 2018;1:885066618775959. https://doi.org/10.1177/0885066618775959.
29. Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth. 2012;108:452-9.
30. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med. 2003;31:104-12.
31. Hampshire PA, Welch CA, McCrossan LA, Francis K, Harrison DA. Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC case mix Programme database. Crit Care. 2009;13:R137. https://doi.org/10.1186/cc8016.
32. Cuthbertson BH, Rajalingham Y, Harrison S, McKirdy F. The outcome of haematological malignancy in Scottish intensive care units. J Intensive Care Soc. 2008;9:135-40.
33. Chi S, Ikezoe T. Disseminated intravascular coagulation in non-Hodgkin lymphoma. Int J Hematol. 2015;102:413-9. https://doi.org/10.1007/s12185-015-1854-5.
34. Radojevic-Skodric S, Bogdanovic L, Jovanovic M, Baralic I, Dzamic Z, Gordon R, Ognjanovic S, Basta-Jovanovic G. Acute renal failure in different malignant tumors. Curr Med Chem. 2016;23:2041-6.